Drug Profile
Research programme: TGF-beta inhibiting protein gene therapy - Zenith Epigenetics Corp
Alternative Names: TGF-β Shield™Latest Information Update: 14 Jun 2013
Price :
$50
*
At a glance
- Originator Resverlogix Corporation
- Class Gene therapies
- Mechanism of Action Gene transference; Transforming growth factor beta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer